ISSN: 2459 - 1777
Volume: 2
Issue: 3
Year: 2017
Two-Year Results of Photodynamic Therapy Combined with Intravitreal Anti-Vascular Endothelial Growth Factor for Polypoidal Choroidal Vasculopathy; A Real Life Experience [Beyoglu Eye J]
Beyoglu Eye J. 2017; 2(3): 90-95 | DOI: 10.14744/bej.2017.14633  

Two-Year Results of Photodynamic Therapy Combined with Intravitreal Anti-Vascular Endothelial Growth Factor for Polypoidal Choroidal Vasculopathy; A Real Life Experience

Sibel Ahmet, Okkes Baz, Gokhan Demir, Ali Demircan, Zeynep Alkin, Abdullah Ozkaya, Alperen Koc, Muhittin Taskapili
University of Healty Sciences, Beyoglu Eye Training and Research Hospital, Istanbul, Turkey

INTRODUCTION: The aim of this study was to evaluate the 2-year outcomes of intravitreal ranibizumab (IVR) therapy in combination with photodynamic therapy (PDT) in patients with polypoidal choroidal vasculopathy (PCV).
METHODS: Patients with PCV who presented at the clinic between January 2013 and January 2014 were reviewed retrospectively. Twenty-three eyes of 23 patients were included in this study. Indocyanine green angiography was performed to confirm the diagnosis of PCV in all patients. IVR was administered within a week following PDT, then followed by additional IVR as needed. Best corrected visual acuity (BCVA) measurement, biomicroscopic examination, and central macular thickness (CMT) measurement via optical coherence tomography at baseline and at 3, 6, 12, 18, and 24 months were performed. The mean change in BCVA and CMT at follow-up was compared with the baseline.
RESULTS: A total of 23 eyes of 23 patients were included in this study. The mean age of the patients was 65.8±7.4 years (range: 55-82 years). The mean BCVA (logMAR, or logarithm of the minimum angle of resolution) was 0.68±0.45 at baseline, 0.67±0.45 at 3 months (p=0.24), 0.66±0.45 at 6 months (p=0.43), 0.69±0.43 at 12 months (p=0.95), 0.69±0.42 at 18 months (p=0.54), and 0.70±0.42 at 24 months (p=0.56). The mean CMT was 334.5±99.4 μm at baseline, 313.4±96.1 μm at 3 months (p=0.27), 319.1±106.5 μm at 6 months (p=0.44), 303.52±128.33 μm (p=0.17) at 12 months, 246.6±80.8μm at 18 months (p=0.0001), and 226.9±71.7 μm at 24 months (p=0.0001).
DISCUSSION AND CONCLUSION: Verteporfin PDT administered in combination with IVR was an effective treatment for preserving VA in PCV for a 2-year period. Our results need to be confirmed in further studies in a real-life setting.

Keywords: Combined therapy, polypoidal choroidal vasculopathy, ranibizumab.


Sibel Ahmet, Okkes Baz, Gokhan Demir, Ali Demircan, Zeynep Alkin, Abdullah Ozkaya, Alperen Koc, Muhittin Taskapili. Two-Year Results of Photodynamic Therapy Combined with Intravitreal Anti-Vascular Endothelial Growth Factor for Polypoidal Choroidal Vasculopathy; A Real Life Experience. Beyoglu Eye J. 2017; 2(3): 90-95

Corresponding Author: Sibel Ahmet, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar




Copyright © 2017 Beyoglu Eye Journal LookUs & Online Makale